Kaplan-Meier analysis of time to systemic metastasis from uveal melanoma based on tumor thickness in 7621 patients. The values in the table are given as the percentage with the event (number failed/number left) at each increasing increment. P values were determined by comparing values with the 0- to 3-mm group using the log-rank test.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Shields CL, Furuta M, Thangappan A, et al. Metastasis of Uveal Melanoma Millimeter-by-Millimeter in 8033 Consecutive Eyes. Arch Ophthalmol. 2009;127(8):989–998. doi:10.1001/archophthalmol.2009.208
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2009
To determine the rate of metastasis of uveal melanoma on the basis of tumor thickness in millimeters.
Retrospective medical record review.
The mean (median) patient age was 58 (59) years. A total of 8033 eyes were examined. Of the 285 eyes with iris melanoma, the mean tumor thickness was 2.7 mm and metastasis occurred in 0.5%, 4%, and 7% at 3, 5, and 10 years, respectively. Of the 492 eyes with ciliary body melanoma, the mean tumor thickness was 6.6 mm and metastasis occurred in 12%, 19%, and 33% at 3, 5, and 10 years, respectively. Of the 7256 eyes with choroidal melanoma, the mean tumor thickness was 5.5 mm and metastasis occurred in 8%, 15%, and 25% at 3, 5, and 10 years, respectively. For all uveal melanoma, metastasis at 5, 10, and 20 years was 6%, 12%, and 20% for small melanoma (0-3.0 mm thickness), 14%, 26%, and 37% for medium melanoma (3.1-8.0 mm), and 35%, 49%, and 67% for large melanoma (>8.0 mm). More specifically, metastasis per millimeter increment at 10 years was 6% (0-1.0 mm thickness), 12% (1.1-2.0 mm), 12% (2.1-3.0 mm), 16% (3.1-4.0 mm), 27% (4.1-5.0 mm), 28% (5.1-6.0 mm), 29% (6.1-7.0 mm), 41% (7.1-8.0 mm), 50% (8.1-9.0 mm), 44% (9.1-10.0 mm), and 51% (>10.0 mm). Clinical factors predictive of metastasis by multivariate analysis included increasing patient age, ciliary body location, increasing tumor diameter, increasing tumor thickness, having a brown tumor, and the presence of subretinal fluid, intraocular hemorrhage, or extraocular extension.
Increasing millimeter thickness of uveal melanoma is associated with increasing risk for metastasis.
In 1962, Paul et al1 from the Armed Forces Institute of Pathology reported the demographic data and prognosis of 3852 patients with uveal melanoma, the largest collection of patients with intraocular melanoma then. Their data revealed the following information: mean age at diagnosis of 55 years, approximately 54% male, and less than 1% African American. On the basis of the follow-up of 2652 cases, mortality rate by actuarial method was 29% at 5 years, 40% at 10 years, and 46% at 15 years, with a median survival of 15+ years. Ten-year mortality was lower in younger patients (aged 20-39 years) at 26% vs older patients (aged >70 years) at 51%. In 1992, Diener-West et al2 provided a meta-analysis of 8 published articles that further refined our understanding of uveal melanoma prognosis by general tumor size. The combined weighted estimate of 5-year mortality was 16% for small tumors, 32% for medium tumors, and 53% for large tumors. Later, the Collaborative Ocular Melanoma Study disclosed melanoma-related mortality at 10 years to be 17% to 18% for medium melanoma and 40% to 45% for large melanoma.3-6
Uveal melanoma prognosis has been shown to be dependent on several clinical factors including tumor location in the ciliary body, large tumor size, diffuse (flat) configuration, and extraocular extension as well as histopathologic and cytogenetic factors including epithelioid cell type, increased mitotic activity, infiltrating lymphocytes, tumor vascular networks, and chromosomal mutations including monosomy 3 and 8q addition.7,8 In several articles, tumor size has been identified as one of the key clinical features predictive of metastasis.9,10 Furthermore, increasing tumor thickness, from small to medium to large, has been correlated with increasing risk for metastasis, but the exact relationship per millimeter of tumor thickness has not been previously addressed, to our knowledge. In this analysis, we evaluate a large cohort of 8033 patients observed long-term for melanoma-related metastasis and correlate metastasis on the basis of a single millimeter increase in tumor thickness.
A retrospective medical record review was performed for all patients with the clinical diagnosis of uveal melanoma managed by the Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania, from August 25, 1970, to August 27, 2008. Institutional review board approval was obtained for this retrospective study. All patients were examined by one of the senior authors (C.L.S. or J.A.S.) using techniques of slitlamp biomicroscopy of the anterior and posterior segments of the eye and indirect ophthalmoscopy of the entire fundus. Details of the uveal melanoma were recorded on large anterior segment or fundus drawings for all patients. Anterior segment or fundus photography or both were performed on patients older than 6 years.
Clinical data were collected at the initial examination for patient age, race/ethnicity, sex, and affected eye. The tumor data included site location of tumor epicenter (iris, ciliary body, choroid), quadrant location of tumor epicenter (inferior, temporal, superior, nasal, macula), clock-hour location of the tumor, anteroposterior location of tumor epicenter (macula, macula-equator, equator–ora serrata), distance of posterior tumor margin to optic disc margin and foveola (expressed in millimeters), and largest tumor basal dimension and thickness (expressed in millimeters). Tumor basal diameter was measured by indirect ophthalmoscopy and tumor thickness by standardized ocular ultrasonography using B scan and A scan measurements. The ultrasonographic examination consisted of a dynamic evaluation of the intraocular tumor with assessment of tumor configuration and acoustic qualities on B scan, internal reflectivity on A scan, and measurement of thickness from tumor apex to base of the choroid on A scan using a perpendicular to the sclera. The ultrasonogram was performed by a single ultrasonographer over the past 20 years or the senior authors (C.L.S. or J.A.S.). Other clinical tumor features included melanoma shape and pigmentation, and related subretinal fluid, Bruch membrane rupture, extraocular extension, and intraocular hemorrhage. The tumor management was recorded. The date and interval to systemic metastasis was recorded. Screening for metastasis was performed by a general medical physician or medical oncologist with twice-yearly physical examination and liver function tests (lactate dehydrogenase, alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase), once-yearly liver imaging (magnetic resonance, computed tomography, or ultrasonography), and chest radiograph.
Comparisons of patient demographic features and tumor features among iris, ciliary body, and choroidal melanoma were performed using analysis of variance (ANOVA) followed by post hoc testing using Bonferroni correction for continuous variables, such as patient age at diagnosis, tumor basal dimension, tumor thickness, and distance of tumor to optic disc margin and foveola. χ2 Testing was performed for the other categorical variables. The specific comparisons between iris melanoma and posterior uveal melanoma were performed using t test for continuous variables, such as patient age at manifestation, tumor basal dimension, tumor thickness, and distance of tumor to optic disc margin and foveola. χ2 Testing was performed for the other categorical variables.
Kaplan-Meier estimates using the product-limit method were calculated for time to melanoma metastasis for iris, ciliary body, choroidal, posterior uveal, and all uveal melanomas. These estimates were provided per 2-mm tumor thickness. The 95% confidence intervals were constructed around the estimates. Log-rank tests were performed to compare the survival distributions of small, medium, and large categories of tumor thickness.
A series of univariate Cox regression analyses were performed to identify the factors predictive of melanoma metastasis in the 8033 patients on the basis of clinical features at manifestation. All of the variables were analyzed as discrete variables except for patient age at manifestation, tumor basal dimension, tumor thickness, and distance of tumor to optic disc margin and foveola, which were evaluated as continuous variables. Subsequent multivariate analyses were performed using the Cox regression forward stepwise method for the factors identified to be significant at the 5% level of significance. Hazard ratios were calculated for each risk factor. Kaplan-Meier estimates were calculated for time to melanoma metastasis for iris, ciliary body, choroidal, posterior uveal, and all uveal melanomas. Kaplan-Meier estimates for time to metastasis per millimeter tumor thickness were calculated.
Of 8033 patients managed on the Oncology Service at Wills Eye Institute, the mean (median) age was 58 (59) years (age range, 3-99 years) and 98% were white (Table 1). Patient demographic data are detailed in Table 1 and tumor features in Table 2. By χ2 test, iris compared with ciliary body melanoma was located more commonly inferior (45% vs 28%, respectively; P < .001) and diffuse (11% vs 2%, respectively; P < .001) and was less often superior (8% vs 27%, respectively; P < .001) (Table 2). Ciliary body compared with choroidal melanoma was located more commonly inferior (28% vs 20%, respectively; P < .001) and less often temporal (19% vs 29%, respectively; P < .001). Clock-hour location of the melanoma did not significantly differ between ciliary body and choroidal tumors, but it did significantly differ between iris and posterior uveal melanoma in that iris tumors were more likely located at the 4- through 7-o’clock positions and less likely at the 9- through 3-o’clock positions. The frequency at the 8-o’clock position did not differ between iris and posterior uveal melanomas.
Of all eyes with uveal melanoma, tumor shape was described in 8012 cases as dome (n = 6044 [75%]), mushroom (n = 1490 [19%]), flat or plateau (n = 463 [6%]), and tapioca (iris tumors) (n = 15 [<1%]). The melanoma was pigmented (n = 4389 [55%]), nonpigmented (n = 1219 [15%]), or mixed pigmentation (n = 2425 [30%]). Other features included subretinal fluid (n = 5667 [71%]), Bruch membrane rupture (n = 1669 [21%]), extraocular extension (n = 222 [3%]), and intraocular hemorrhage (vitreous or subretinal) (n = 821 [10%]). Initial melanoma management included plaque radiotherapy (n = 5048 [63%]), enucleation (n = 2261 [28%]), transpupillary thermotherapy (n = 1775 [22%]), laser photocoagulation (n = 418 [5%]), surgical excision (n = 396 [5%]), external beam radiotherapy (n = 39 [<1%]), particle beam radiotherapy (n = 31 [<1%]), cryotherapy (n = 19 [<1%]), orbital exenteration (n = 16 [<1%]), and observation (n = 494 [6%]).
Tumor size significantly differed depending on tumor location (Table 2). The median tumor base was significantly smaller for iris (5.5 mm) compared with ciliary body (11.0 mm) (P < .001) melanoma, whereas ciliary body (11.0 mm) compared with choroidal (11.0 mm) melanoma base did not differ. The median tumor thickness was significantly less for iris (2.1 mm) compared with ciliary body (6.0 mm) (P < .001) melanoma and for choroidal (4.5 mm) compared with ciliary body (6.0 mm) (P < .001) melanoma.
During the mean (median) follow-up of 52 (35) months (range, 0-436 months), melanoma-related metastasis was found in 957 patients (12%), including iris (8 of 285 [2.8%]), ciliary body (70 of 492 [14.2%]), ora serrata–equator (226 of 1217 [18.6%]), equator-macula (632 of 5622 [11.2%]), and macula (21 of 417 [5.0%]).
Of the 285 eyes with iris melanoma, the mean tumor base was 6.5 mm and thickness was 2.7 mm (Table 2). At 3, 5, and 10 years follow-up, metastasis was found in 0.5%, 4.1%, and 6.9%, respectively. At 10 years follow-up, metastasis occurred in 11.1% (0-1.0 mm thickness), 4.7% (1.1-2.0 mm), 8.4% (2.1-3.0 mm), 25% (3.1-4.0 mm), and 12.5% (>4.0 mm), respectively (Table 3).
Of the 492 eyes with ciliary body melanoma, the mean tumor base was 11.7 mm and thickness was 6.6 mm (Table 2). At 3, 5, and 10 years follow-up, metastasis was found in 12%, 19%, and 33%, respectively. At 10 years follow-up, metastasis occurred in 25% (0-1.0 mm thickness), 24% (1.1-2.0 mm), 15% (2.1-3.0 mm), 19% (3.1-4.0 mm), 32% (4.1-5.0 mm), 22% (5.1-6.0 mm), 35% (6.1-7.0 mm), 46% (7.1-8.0 mm), 82% (8.1-9.0 mm), 32% (9.1-10.0 mm), and 43% (>10.0 mm) (Table 4).
Of the 7256 eyes with choroidal melanoma, the mean tumor base was 11.3 mm and thickness was 5.5 mm (Table 2). At 3, 5, and 10 years follow-up, metastasis was found in 8%, 15%, and 25%, respectively. At 10 years follow-up, metastasis occurred in 5% (0-1.0 mm thickness), 12% (1.1-2.0 mm), 12% (2.1-3.0 mm), 16% (3.1-4.0 mm), 26% (4.1-5.0 mm), 28% (5.1-6.0 mm), 28% (6.1-7.0 mm), 41% (7.1-8.0 mm), 48% (8.1-9.0 mm), 44% (9.1-10.0 mm), and 52% (>10.0 mm) (Table 5). Results for posterior uveal melanoma (ciliary body and choroidal) are listed in Table 6.
Of all eyes with uveal (iris, ciliary body, and choroidal) melanoma, metastasis was found in 8%, 15%, and 25% at 3, 5, and 10 years follow-up, respectively. At 10 years follow-up, metastasis occurred in 6% (0-1.0 mm thickness), 12% (1.1-2.0 mm), 12% (2.1-3.0 mm), 16% (3.1-4.0 mm), 27% (4.1-5.0 mm), 28% (5.1-6.0 mm), 29% (6.1-7.0 mm), 41% (7.1-8.0 mm), 50% (8.1-9.0 mm), 44% (9.1-10.0 mm), and 51% (>10.0 mm) (Table 7). At 10 years follow-up, metastasis occurred in 12% of small melanoma (0-3.0 mm thickness), 26% of medium melanoma (3.1-8.0 mm thickness), and 49% of large melanoma (>8.0 mm) (Figure). At 20 years follow-up, metastasis occurred in 20% of small melanoma, 37% of medium melanoma, and 67% of large melanoma (Figure).
By multivariate analysis, factors predictive of metastasis from uveal melanoma include increasing patient age, ciliary body location, increasing tumor diameter, increasing tumor thickness, brown tumor, and the presence of subretinal fluid, intraocular hemorrhage, or extraocular extension (Table 8). Each millimeter increase in thickness showed a 1.06 hazard ratio.
One of the most important clinical features for estimation of uveal melanoma prognosis is tumor size.2,7,9-11 Tumor size is most often measured in chord or arc length of largest basal diameter and greatest tumor thickness. The basal diameter is estimated through ophthalmoscopic judgment or measured with ultrasonography, transillumination, or digital photography calipers. Tumor thickness is measured by ultrasonographic calipers. According to the Collaborative Ocular Melanoma Study, ultrasonography measurement of tumor thickness is relatively accurate and was within 2 mm of histopathologic measurement of thickness in 90% of eyes.12 However, basal diameter estimates by ultrasonography showed poorer accuracy, as correlation within 2 mm of histopathology measurements was noted in only 58% of cases. Most studies on prognosis have used either basal diameter or thickness as the basis for estimating prognosis. For accuracy and reproducibility reasons, we have historically preferred thickness measurements.
In 1980, McLean et al13 analyzed the natural history of uveal melanoma in 2055 cases managed with enucleation between 1940 and 1960 and filed in the Registry of Ophthalmic Pathology. The tumor size was measured on gross examination of the globe and classified into small (<11 mm diameter), medium (11-15 mm diameter), or large (>15 mm diameter). At 10 years follow-up, actuarial survival was 81% for small melanoma, 60% for medium melanoma, and 35% for large melanoma.
In 2003, Kujala et al9 evaluated long-term prognosis of 289 patients with uveal melanoma who were observed for a median of 28 years. By Kaplan-Meier analysis, they found melanoma metastasis at 32% by 5 years, 50% by 15 years, 56% by 25 years, and 62% by 35 years. Of those who died of uveal melanoma, death occurred within 15 years in 90% and 25 years in 98%. Tumor size was graded by diameter (without thickness measurement) and Kaplan-Meier estimates for melanoma-related mortality for 5, 15, 25, and 35 years at 8%, 12%, 18%, and 42%, respectively, for small tumors (<10 mm basal diameter), 32%, 48%, 60%, and 60%, respectively, for medium tumors (10-15 mm basal diameter), and 50%, 63%, 66%, and 75%, respectively, for large tumors (>15 mm basal diameter). Each millimeter increase in tumor diameter showed a 1.08 hazard ratio.
Diener-West et al2 performed a meta-analysis of published articles about uveal melanoma prognosis based on tumor size graded as small, medium, or large. As this was a meta-analysis, there were numerous individual definitions for each size category. The tumor size definition varied per article with small tumors defined as one of the following: less than 3 mm thickness and less than 10 mm diameter, less than 10 mm diameter, less than or equal to 10 mm diameter, less than 11 mm diameter, less than 11 mm diameter or less than or equal to 2 mm high, or less than 300 mm3. Medium tumors were defined as 10 to 15 mm diameter, 11 to 15 mm diameter, 11 to 15 mm diameter or 3 to 5 mm high, or less than or equal to 15 mm diameter. Large tumors were defined as greater than 15 mm diameter or greater than 15 mm diameter or greater than 5 mm high. They found 5-year all-cause mortality to be 16% for small melanoma, 32% for medium melanoma, and 53% for large melanoma. They recognized the difficulties in conducting their meta-analysis for mortality rates from the few published articles, heterogeneous populations and treatments, different methods of reporting mortality, and, importantly, difference in definitions of tumor size.
The Collaborative Ocular Melanoma Study (COMS) conducted 2 multicenter trials regarding therapy for uveal melanoma. In the medium-sized tumor trial (2.5-10 mm thickness and basal diameter <16 mm), eyes were randomized to iodine I 125 brachytherapy or enucleation. In this trial, melanoma-related mortality at 5, 10, and 12 years was 10%, 18%, and 21%, respectively, for patients in the 125I brachytherapy treatment arm and 11%, 17%, and 17%, respectively, for those in the enucleation treatment arm.3,4 In the large tumor trial (>10 mm thickness or >2 mm thickness and >16 mm basal diameter), eyes were randomized to enucleation or external beam radiotherapy preceding enucleation. In that trial, melanoma-related mortality at 5 and 10 years was 28% and 40%, respectively, for patients in the enucleation treatment arm and 26% and 45% in the external beam radiotherapy preceding enucleation treatment arm.5,6
In our analysis, we attempted to maintain simplicity, accuracy, and reproducibility of tumor measurement for the ample cohort of 8033 eyes with melanomas. The tumor dimensions were described as basal diameter by clinical estimation by 2 experienced observers (C.L.S. and J.A.S.) and tumor thickness by ultrasonographic measurement in every case. Thickness measurement by ocular ultrasonography was believed to represent a relatively nonarbitrary measurement of tumor size. Tumor thickness at diagnosis was a mean of 2.7 mm for iris melanoma, 6.6 mm for ciliary body melanoma, and 5.5 mm for choroidal melanoma. In our analysis, melanoma size was not artificially classified into small, medium, or large, but instead was based on exact millimeter thickness. The multivariate analysis revealed tumor thickness as a significant factor predictive of metastasis and each millimeter increase imparted a 1.06 hazard ratio. The rate of melanoma-related metastasis at 10 years based on exact tumor thickness was 6% (0-1.0 mm thickness), 12% (1.1-2.0 mm), 12% (2.1-3.0 mm), 16% (3.1-4.0 mm), 27% (4.1-5.0 mm), 28% (5.1-6.0 mm), 29% (6.1-7.0 mm), 41% (7.1-8.0 mm), 50% (8.1-9.0 mm), 44% (9.1-10.0 mm), and 51% (>10.0 mm) (Table 7).
The metastatic potential was further refined based on tumor location in the iris, ciliary body, choroid, and entire posterior uvea (ciliary body and choroid) (Tables 3-6). The 10-year rate of metastasis for a 3.5- mm-thick melanoma in the ciliary body was 19%, choroid was 17%, and posterior uvea was 17%. A comparison of metastatic potential at different sites with different sizes can quickly be understood using the data in the tables. For example, a melanoma measuring 2, 5, or 8 mm thickness developed metastasis at 10 years in 24%, 32%, and 46%, respectively, if in the ciliary body compared with 13%, 26%, and 41%, respectively, if in the choroid (Tables 4 and 5).
In the entire group of 8033 patients, a gradual increasing risk for metastasis was noted with increasing thickness with the exception of the relatively thin (diffuse) melanomas, measuring 2 mm or less in thickness. Iris melanoma from 0 to 1.0 mm and ciliary body or choroidal melanoma from 1.1 to 2.0 mm imparted a slightly higher metastatic rate than those slightly thicker, believed to be caused by the inclusion of a subset of melanoma termed diffuse melanoma. Diffuse melanoma is a variant of melanoma that exhibits horizontal growth pattern in a relatively flat configuration and displays a more aggressive course with invasion of the sclera, extrascleral extension, epithelioid cell type, and higher rate of metastasis.14 In this analysis, diffuse melanoma represented 3% of all uveal melanoma, and specifically included 3% of choroidal, 2% of ciliary body, and 11% of iris melanomas. Diffuse melanoma imparted a 3.84 relative risk for metastasis compared with a nondiffuse melanoma and specifically a 3.26 to 4.76 relative risk for metastasis compared with nondiffuse melanoma at any specific clock hour (Table 8). It is recognized in the literature that this thin variant of melanoma imparts greater metastatic risk when in the choroid or in the iris.14,15
The most important factor for metastasis from cutaneous melanoma remains tumor thickness.16-20 The standard method for measuring cutaneous melanoma thickness is by histologic Breslow depth as measured from the granular layer of the epidermis down to the deepest point of invasion. The TNM classification of melanoma uses Breslow thickness as the main indicator of “T,” representing tumor size. In an analysis of 5702 patients with cutaneous melanoma in Germany, comparing results from melanoma in the head/neck region to other sites, it was found that the variable with the highest prognostic effect was tumor thickness.16 An analysis of Medicare patients in the United States showed that those with cutaneous melanoma detected by dermatologists (compared with nondermatologists) had better survival primarily because of earlier tumor stage (P < .01) and thinner tumor (0.86 mm vs 1.0 mm, P < .05).17 Comparing patient survival with cutaneous melanoma in the United Kingdom vs Australia, it was found again that tumor thickness was the most important factor.18 Sartore et al19 reported that sentinel lymph node metastasis from cutaneous melanoma was minimized in thin tumors (<1.19 mm thickness) and those that lacked ulceration and lymphovascular invasion. Recent developments for measurement of exact in vivo thickness of cutaneous melanoma using 75-MHz ultrasonography has been explored and found to show reliable correlation with pathologic Breslow thickness.20
Uveal melanoma size is not the only factor related to prognosis. There are numerous factors to consider, but tumor size continues to be one of the most important clinical factors. Coupland et al21 evaluated 847 patients with uveal melanoma for metastatic death and found clinical and histopathologic predictive factors of largest basal tumor diameter, closed loops, epithelioid cells, mitotic rate, and extraocular spread. Damato et al22 included genetic testing in their analysis for factors predictive of metastatic death and found the most important independent predictors to be basal tumor diameter, chromosome 3 loss, and epithelioid cell histopathology. Eskelin et al23 explored tumor doubling times and speculated that most metastases initiate 5 years before primary treatment. Further theoretical analysis revealed estimates that metastases occur at an approximate tumor volume of 7 mm3, when the tumor is clinically visible at roughly 3 mm diameter and 1.5 mm thickness.24
Screening for metastasis from choroidal melanoma generally includes twice-yearly liver function tests (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, or bilirubin levels) and physical examination and once-yearly liver and lung imaging. However, there remains debate on which tests have the highest yield and most beneficial cost-effectiveness.25,26 Eskelin et al25 evaluated 46 consecutive patients with metastatic uveal melanoma who were screened with liver function tests, chest radiograph, and abdominal ultrasonography. They found that the lactate dehydrogenase level was the most sensitive liver function test. In addition, they noted that semiannual screening with liver function tests and abdominal ultrasonography detected disease in more than 95% of patients while they were still asymptomatic. Chest radiography was found to be insensitive. Our protocol is similar to that used by Eskelin et al. A different approach was used in the COMS, in which 2320 patients were screened annually with liver function tests. If the test results were elevated, a diagnostic or imaging test was performed. They found that the sensitivity, specificity, and positive and negative predictive values associated with one abnormal liver function test for metastasis was 15%, 92%, 46%, and 71%, respectively.26 They concluded that their approach showed high specificity but low sensitivity and advised better tests to detect metastatic disease.26
In this analysis, we correlated long-term prognosis in a refined and practical millimeter-by-millimeter fashion, using ultrasonography for accurate measurements. These data are applicable for the practicing clinician in that they are simple and useful in the clinic setting. This is especially practical for those patients who do not undergo genetic sampling or those who do not have histopathologic assessment owing to treatment with nonenucleation methods. Knowledge of the approximate risk for melanoma-related metastasis based on accurate measurement of thickness and the added risk of each millimeter of thickness could ultimately affect the therapeutic decision.
Correspondence: Carol L. Shields, MD, Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, 840 Walnut St, Ste 1440, Philadelphia, PA 19107 (firstname.lastname@example.org).
Submitted for Publication: January 6, 2009; final revision received March 20, 2009; accepted March 26, 2009.
Author Contributions: Dr C. L. Shields had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Financial Disclosure: None reported.
Funding/Support: This study was support by the Retina Research Foundation of the Retina Society (Dr C. L. Shields), the Paul Kayser International Award of Merit in Retina Research (Dr J. A. Shields), a donation from Michael, Bruce, and Ellen Ratner (Drs C. L. and J. A. Shields), Mellon Charitable Giving from the Martha W. Rogers Charitable Trust (Dr C. L. Shields), and the Eye Tumor Research Foundation (Drs C. L. and J. A. Shields).
Role of the Sponsor: The funders had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.
Additional Contributions: Rishita Nutheti, PhD, provided statistical analysis.
Create a personal account or sign in to: